BEIJING, China, Feb. 10, 2026 — DIFF Biotech announced that its proprietary intranasal influenza vaccine candidate, DIFF-flu, has received clinical trial authorization from China’s National Medical Products Administration (NMPA) as a Class 1.2 innovative vaccine. The approval enables first-in-human evaluation of the attenuated live vaccine and marks a significant development in China’s domestically developed respiratory immunization pipeline. The candidate represents the country’s first self-developed nasal spray influenza vaccine to advance into clinical testing, leveraging a novel gene-modification attenuation platform.
Science Significance
DIFF-flu introduces an M2 gene-modified attenuation strategy designed to create a replication-restricted influenza strain, balancing strong immunogenicity with enhanced safety. Unlike conventional cold-adapted live attenuated influenza vaccines, which rely on temperature sensitivity to limit viral replication, this platform genetically restricts replication capacity. The approach functions as a biological “safety harness,” enabling immune activation while minimizing uncontrolled viral spread. Preclinical evaluations demonstrated negligible viral shedding and reduced respiratory viral loads, suggesting improved tolerability. Additionally, the vaccine generated broad immune responses, including protection against historical epidemic strains and reactivity to contemporary circulating variants. This dual-spectrum immunogenicity underscores the platform’s potential as a next-generation mucosal vaccine technology.
Regulatory Significance
Clinical trial clearance from the NMPA establishes a critical regulatory milestone for innovative vaccine platforms in China. Class 1.2 designation reflects recognition of the vaccine’s novel mechanism and domestic innovation status. Authorization permits progression into human safety and immunogenicity studies under Good Clinical Practice frameworks. The approval also signals regulatory openness toward gene-modified attenuation technologies and intranasal delivery systems. As global regulators expand pathways for innovative biologics, DIFF-flu’s advancement contributes to evolving evaluation models for live attenuated respiratory vaccines, including viral shedding controls, environmental biosafety, and mucosal immunity endpoints.
Business Significance
Advertisement
The influenza vaccine market is undergoing structural transformation, creating commercial opportunity for differentiated intranasal platforms. Injectable vaccines remain dominant but face uptake limitations and modest transmission-blocking capability. Nasal spray vaccines, which induce immunity at viral entry sites, are gaining strategic attention. DIFF-flu’s proprietary attenuation technology and international patent protection strengthen its lifecycle value and industrialization prospects. Market expansion is further supported by global policy shifts favoring at-home vaccination models and direct-to-consumer distribution pathways. As manufacturing scale-up and commercialization planning progress, DIFF Biotech is positioned to compete within the multibillion-dollar global influenza prevention market.
Patients’ Significance
Intranasal vaccination offers a needle-free, accessible immunization route that may improve compliance across diverse populations. Traditional live attenuated nasal vaccines are often unsuitable for older adults or immunocompromised individuals due to residual replication risk. DIFF-flu’s replication-restricted design may expand eligibility to these underserved groups. Enhanced mucosal immunity could also improve frontline viral defense, reducing infection severity and transmission. With seasonal influenza infecting up to one billion individuals annually and causing hundreds of thousands of deaths, improved vaccine platforms hold substantial clinical relevance, particularly for high-risk aging populations.
Policy Significance
The advancement of domestically developed intranasal vaccines aligns with national immunization security and global pandemic preparedness priorities. Governments are increasingly investing in respiratory vaccine innovation to strengthen herd immunity and reduce healthcare system burden. Improved delivery technologies may support mass vaccination campaigns, decentralized distribution, and emergency outbreak response. Low vaccination coverage in several regions — including single-digit uptake rates in parts of Asia — underscores the urgency of expanding access through convenient, scalable immunization solutions. Regulatory endorsement of innovative attenuation technologies may also accelerate policy frameworks supporting mucosal vaccine adoption.
With clinical authorization secured, DIFF-flu enters a pivotal translational phase bridging genetic attenuation science and human immunization outcomes. The convergence of replication-restricted engineering, intranasal delivery, and broad-spectrum immune activation positions the candidate as a notable entrant in next-generation influenza prevention. Upcoming clinical data will determine its safety profile, immunogenic durability, and potential role in reshaping respiratory vaccination strategies across global markets.
Source: DIFF Biotech press release
